Current reports
6-K
Current report (foreign)
30 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
4 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Current report (foreign)
29 Mar 24
6-K
Current report (foreign)
22 Mar 24
6-K
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
21 Mar 24
6-K
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
20 Mar 24
6-K
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
9 Feb 24
6-K
Current report (foreign)
31 Jan 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
20 Dec 23
424B5
Prospectus supplement for primary offering
15 Dec 23
424B5
Prospectus supplement for primary offering
31 Oct 23
424B5
Prospectus supplement for primary offering
15 Sep 23
424B5
Prospectus supplement for primary offering
13 Sep 23
FWP
Free writing prospectus
28 Jul 23
424B5
Prospectus supplement for primary offering
28 Jul 23
424B3
Prospectus supplement
15 Jun 23
F-1/A
Registration statement (foreign) (amended)
9 Jun 23
F-1/A
Registration statement (foreign) (amended)
8 Jun 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
15 Jun 23
EFFECT
Notice of effectiveness
15 Jun 23
CORRESP
Correspondence with SEC
12 Jun 23
CORRESP
Correspondence with SEC
12 Jun 23
UPLOAD
Letter from SEC
12 Jun 23
CORRESP
Correspondence with SEC
2 Jun 23
UPLOAD
Letter from SEC
30 May 23
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
28 Feb 23
CORRESP
Correspondence with SEC
23 Feb 23
Ownership